PROTEOME SCIENCES PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.05 GBX | +4.92% |
|
+18.08% | -10.60% |
| May. 16 | Proteome Sciences promises AGM return to growth in 2024 | AN |
| May. 16 | AIM WINNERS & LOSERS: Proteome Sciences eyes return to growth in 2024 | AN |
| Sales 2022 | 7.78M 9.91M | Sales 2023 | 5.03M 6.41M | Capitalization | 13.37M 17.04M |
|---|---|---|---|---|---|
| Net income 2022 | 1M 1.27M | Net income 2023 | -2M -2.55M | EV / Sales 2022 | 2.35 x |
| Net Debt 2022 | 7.92M 10.09M | Net Debt 2023 | 11.45M 14.59M | EV / Sales 2023 | 4.94 x |
| P/E ratio 2022 |
8.14
x | P/E ratio 2023 |
-5.46
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 80.53% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +4.92% | ||
| 1 week | +18.08% | ||
| 1 month | +15.38% | ||
| 3 months | -2.64% | ||
| 6 months | -20.59% | ||
| Current year | -10.60% |
1 week
3.38
3.75
1 month
3.004.50
Current year
2.655.75
1 year
2.658.79
3 years
2.658.79
5 years
2.2510.00
10 years
2.2043.00
| Managers | Title | Age | Since |
|---|---|---|---|
Mariola Söhngen
CEO | Chief Executive Officer | 63 | 20-09-14 |
Abdelghani Omari
DFI | Director of Finance/CFO | 48 | 22-08-31 |
| Chairman | 71 | 93-12-09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | 93-12-09 | |
Roger McDowell
BRD | Director/Board Member | 69 | 14-06-30 |
Ursula Ney
BRD | Director/Board Member | 72 | 17-07-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 4.05 | +4.92% | 72,225 |
| 24-05-30 | 3.86 | +2.93% | 100,000 |
| 24-05-29 | 3.75 | -0.27% | 0 |
| 24-05-28 | 3.76 | +9.62% | 297,489 |
| 24-05-24 | 3.43 | -4.72% | 50,346 |
Delayed Quote London S.E., May 31, 2024 at 11:35 am EDT
More quotes
Proteome Sciences plc is a specialist provider of contract proteomics services. The Companyâs services enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. Its principal activities involve protein biomarker research and development. It uses high-sensitivity techniques to detect and characterize differentially expressed proteins in biological samples for diagnostic, prognostic and therapeutic applications. SysQuant and TMT MS2 are unbiased methods for identifying and contextualizing new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. In addition, it has invented and developed the technology for TMT and TMTpro, and manufactures these small, protein-reactive chemical reagents for multiplex quantitative proteomics.
Calendar
2024-07-24
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -10.60% | 15.21M | |
| -7.16% | 178B | |
| -1.23% | 107B | |
| -4.86% | 67.04B | |
| -4.28% | 47.23B | |
| +10.32% | 44.62B | |
| +8.14% | 42.5B | |
| +15.76% | 29.99B | |
| +15.53% | 25.22B | |
| -5.88% | 24.14B |
- Stock Market
- Equities
- PRM Stock
